Second Date For Merck: Retrial Set For Feb. 6
This article was originally published in The Pink Sheet Daily
Executive Summary
A retrial of the first federal Vioxx product liability case is scheduled to begin on Feb. 6, the firm announced
You may also be interested in...
Win, Lose & Draw: Third Merck Vioxx Trial Ends In Mistrial
A Houston jury was unable to reach a verdict in the first federal product liability trial over the COX-2 inhibitor.
Vioxx Cardiovascular Outcomes Withheld From VIGOR Article, NEJM Says
Additional cardiovascular events from the VIGOR study were known by study authors but not included in the manuscript submission to the New England Journal of Medicine, the journal says.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.